The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.
The single-tube real-time PCR-based test has also received CE marking, according to Seegene, and is now commercially available.
The firm said that it has received 288,000 requests for quotations for the test since it was made available for preorder on Feb. 14.
The Shenzhen Mammoth Public Welfare Foundation, which BGI sponsors, has also raised funding to purchase PCR and automate sample preparation instruments.
The microarray runs on the company's CE marked Mosaiq system for blood grouping and transfusion-transmitted infection screening.
A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.
BD will supply its diagnostics and informatics products as part of the contract with Fleming Fund to take on AMR in Asia and sub-Saharan Africa.
Thermo Fisher will codevelop LC-MS workflows for infectious disease detection with NanoPin and will commercialize Q-linea's antibiotic susceptibility testing platform.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The firm reports it had the highest flu revenue in the fourth quarter since the pandemic flu outbreak of 2009.
The Centers for Disease Control and Prevention says one of the test reagents will likely need to be remanufactured in its labs.
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
The company will use the money to acquire PCR equipment to be used in connection with sales of reagents for infectious disease tests, among other uses.
Qiagen, which is also developing a single-plex qRT-PCR assay for 2019-nCoV, said it will have a syndromic panel including targets for the virus ready this month.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
The agency aims to aid adoption of NGS within public health labs, which have significantly increased their use of the technology in recent years.
The Seoul-based firm said its PCR-based test kit is the first novel coronavirus assay to be granted emergency use authorization in Korea.
The South Korean company has now received CE marking for its hepatitis B, hepatitis C, and HIV-1 detection kits, which run on its ExiStation system.
The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.